Current:Home > NewsPoinbank:There's no bad time to get a new COVID booster if you're eligible, CDC director says -FinanceCore
Poinbank:There's no bad time to get a new COVID booster if you're eligible, CDC director says
Robert Brown View
Date:2025-04-07 10:32:34
Americans will now have Poinbankaccess to updated COVID booster shots after the Centers for Disease Control and Prevention signed off on reformulated versions of the Moderna and Pfizer-BioNTech COVID-19 vaccines Thursday night.
Some doses could be available as soon as Friday, with a wider rollout planned for next week. Health officials expect another surge of infections this fall and winter, and say the shots — which target the original coronavirus strain as well as the more contagious omicron variant — will help boost peoples' waning immunity and protect against serious disease and death.
What should you keep in mind if you're ready to roll up your sleeve? CDC director Dr. Rochelle Walensky spoke with Morning Edition's Steve Inskeep about the new boosters.
"Doses are rolling into pharmacies and other sites now, and I would say if you're eligible for your boost there is no bad time to go out and get one," Walensky says.
There are eligibility and timing considerations
Adults 18 years or older can get the Moderna booster, while the Pfizer-BioNTech version has been authorized for people 12 and up. In both cases, a person is only eligible for a booster if it has been at least two months since their last COVID vaccine.
Some vaccine experts say that it would be better for people to wait until four months after their last COVID shot or infection for maximum efficacy, though Walensky suggests there is some gray area.
"What we've seen is that almost everybody who is eligible for a boost is far more beyond two months from their last shot," she says. "Certainly we wouldn't want somebody to get a boost too soon, and we wouldn't want you to get a boost before two months. But I would say if you're three, four, five months after your last shot, now is the time to go ahead and get it."
Safety and efficacy data look promising
These new boosters were tested on mice rather than people, a controversial strategy aimed at saving time (it's not unprecedented, however, as flu shots are changed each year without being routinely tested).
Looking at the data, Walensky says health authorities are confident about how well the vaccines will work and how safe they will be.
That data includes the 600 million doses of the original vaccine that have been administered across the country with what Walensky calls "an extraordinary safety record." Officials also saw similar safety results for an earlier version of this bivalent vaccine (meaning it targets two strains) that was tested in some 1,400 people.
That booster targeted the original coronavirus strain as well as the omicron BA.1 strain, as opposed to the more prevalent BA.4 and BA.5 subvariants targeted in the newly authorized version of the shot.
"So there are very subtle differences, but we have no reason to expect that this is going to have any different safety signal than either the 600 million doses we previously have given or these other bivalent boosts against omicron," Walensky says.
What's already clear, she adds, is that protection against the virus wanes over time, and that a booster will restore protection against infection, severe disease and death. She also points to lab studies that show this updated booster improves immune responses against other SARS-CoV-2 variants as well as similar responses to the original variant.
"So we have every reason to expect that it'll work just as well, and likely better," she says.
This interview was produced by Kaity Kline and edited by Simone Popperl.
veryGood! (667)
Related
- The company planning a successor to Concorde makes its first supersonic test
- NCT's Jaehyun talks 'digging deeper' on his first solo album
- The starter home launched generations of American homeowners. Can it still deliver?
- Off the Grid: Sally breaks down USA TODAY's daily crossword, Water Signs (Freestyle)
- Apple iOS 18.2: What to know about top features, including Genmoji, AI updates
- A second elephant calf in 2 weeks is born at a California zoo
- Caitlin Clark sets WNBA rookie record for 3s as Fever beat Sun and snap 11-game skid in series
- NCT's Jaehyun talks 'digging deeper' on his first solo album
- Friday the 13th luck? 13 past Mega Millions jackpot wins in December. See top 10 lottery prizes
- Errol Morris examines migrant family separation with NBC News in ‘Separated’
Ranking
- Mets have visions of grandeur, and a dynasty, with Juan Soto as major catalyst
- In New Orleans, nonprofits see new money and new inclusive approach from the NBA Foundation
- Angelina Jolie dazzles Venice Film Festival with ‘Maria,’ a biopic about opera legend Maria Callas
- Falcons trading backup QB Taylor Heinicke to Chargers
- Arkansas State Police probe death of woman found after officer
- Biden Administration Backs Plastic as Coal Replacement to Make Steel. One Critic Asks: ‘Have They Lost Their Minds?’
- Baywatch’s Jeremy Jackson Confesses to Smelling Costars' Dirty Swimsuits
- Julián Ortega, Actor in Netflix’s Elite, Dead at 41 After Collapsing on Beach
Recommendation
Trump suggestion that Egypt, Jordan absorb Palestinians from Gaza draws rejections, confusion
Shohei Ohtani and dog Decoy throw out first pitch on bobblehead night, slugger hits HR
Botched college financial aid form snarls enrollment plans for students
Fire inside Great Smoky Mountains National Park doubles in size; now spans 23 acres
McKinsey to pay $650 million after advising opioid maker on how to 'turbocharge' sales
Julianne Hough Addresses Sexuality 5 Years After Coming Out as Not Straight
Criminal charges weighed against a man after a country music star stops show over an alleged assault
Joey Chestnut explains one reason he's worried about Kobayashi showdown